TP53 and neoplasm: To enhance prognostic assessment, the CLL-IPI (CLL International Prognostic Index) was introduced, incorporating the biological factors of the leukemia (TP53 and IGHV mutation status) along with tumor burden (clinical stage and beta-2-microglobulin levels) and age.